GlaxoSmithKline is under pressure from not one, but two regulatory bodies to get problems under control at a flu vaccine plant in Canada. After the FDA handed the company a warning letter late last month, Health Canada now says the pharma giant has a month to lay out a plan for resolving issues there.
Researchers at La Jolla Institute for Allergy and Immunology in California are spearheading an effort to develop the first vaccine for heart disease.
Pfizer and Novartis have been racing to get their meningitis B vaccines to market for years. But as of Tuesday, the contest has never been closer, with both companies submitting approval applications to the FDA. Now, it's up to the agency to decide which shot gets the green light first--and first crack at the wide-open patient pool that comes with it.
The vaccine market has long been dominated by the Big 3--Sanofi, Merck and GlaxoSmithKline--with Pfizer and Novartis trailing the trio on the list of revenue-generators. But things are changing at the top.
In a discovery that could put a vaccine for malaria closer in sight, scientists have linked a protein to an essential function in malaria-causing parasites that enables them to escape from inside red blood cells and infect the rest of the body.
When looking for celebrity spokespeople, pharma companies want someone who can deliver a health message as a peer might. And for Sanofi, which is trying to spread the word about the importance of meningitis booster shots--amid lagging sales of its vaccines for the deadly disease--that person is 12-time Olympic medalist swimmer Dara Torres.
According to a new survey, more than two in three mothers have little to no knowledge of the CDC's recommendations for preventing meningococcal meningitis. And if you're a meningitis vaccine maker like Sanofi, that's a troubling statistic
The U.K.'s Joint Committee on Vaccination and Immunization (JCVI) is revising its stance on Novartis' meningitis B vaccine Bexsero. The jab, originally left off Britain's routine vaccination schedule, has gained the JCVI's nod, supplying a needed boost for the Swiss company's flailing vaccine unit.
Researchers have shown in early tests that a nasal vaccine for West Nile virus is effective in mice after two doses as opposed to the traditional three for other vaccines. Currently, no vaccine for the disease is available for humans, despite its recent spread in the U.S. and Canada.
It turns out that Germany will not be the only country facing a shortage of GlaxoSmithKline's chickenpox vaccines. While healthcare providers there have already been given a heads up to prepare for rationing, the company says deliveries worldwide will be affected.